Nasdaq's AI Rally Falters Amid Economic Concerns

The Nasdaq concluded the week with a decline, marking its largest drop since April. Investor apprehension about the AI rally halted notable gains, especially in chip and tech sectors. Meanwhile, the U.S. Treasury yields fell, influenced by diminished consumer sentiment and lengthy government shutdown effects.


Devdiscourse News Desk | Updated: 08-11-2025 05:54 IST | Created: 08-11-2025 05:54 IST
Nasdaq's AI Rally Falters Amid Economic Concerns
This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

The Nasdaq has seen a significant decline, ending the week with its biggest dip since April. This downturn is primarily linked to investor concerns regarding the sustainability of a rally in artificial intelligence stocks. Notably, major chip and tech-related shares were among the week’s biggest losers, contributing to the overall 3% drop in the Nasdaq.

Despite a previous surge driven by optimism surrounding AI technologies, recent warnings, like those from Nvidia's CEO about China potentially leading the AI race, have led to a selloff in this sector. According to Michael O'Rourke, chief strategist at JonesTrading, this reflects a recalibration in the market as investors reevaluate stock valuations, coupled with some profit-taking after a strong year.

Additionally, the impact of the U.S. government’s prolonged shutdown manifests in consumer sentiment, which has reached its lowest point since June 2022, affecting U.S. Treasury yields. This economic uncertainty contrasts with slight gains seen by the S&P 500 and Dow Jones indices, which reported progress in ending the government stalemate.

TRENDING

DevShots

Latest News

OPINION / BLOG / INTERVIEW

Cyber-resilient electric mobility: AI shields EV charging stations from cyber-attacks

AI can decode medical records with near-human accuracy

New AI model could save historic monuments before they crumble

How AI systems must prove trust, transparency and reliability before clinical use

Connect us on

LinkedIn Quora Youtube RSS
Give Feedback